Should I buy, hold, or sell BNTC stock right now?

Benitec Biopharma Inc. (BNTC) currently earns a Roarable Rating of E (Strong Sell — SELL) with 30/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is BNTC's 12-month price target and RQD AI Jury consensus?

BNTC's 12-month base price target is $7.42 (range $5.79 to $17.13), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / BNTC

IRD (23) VOGX (45) PRLD (33) ENTA (20) ⌘ Pro Terminal →

Benitec Biopharma Inc. (BNTC) — RQD Stock Rating Cockpit

$8.49 -2.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.43

Benitec Biopharma Inc. (BNTC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $304.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BNTC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BNTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Benitec Biopharma Inc. (NASDAQ: BNTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $8.49 (-2.86% 1D, market cap $304.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BNTC ranks #795 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BNTC compare to IRD and VOGX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BNTC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRD (Opus Genetics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M) and VOGX (Vogenx Inc) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $300.8M). Among the 5-stock peer group, BNTC leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BNTC?

▼

Per BNTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001808898), Benitec Biopharma Inc. generated $116.9M in revenue (+85.7% YoY), -$37.9M in net income, and -$23.6M in free cash flow against $190.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.43 (-0.70%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BNTC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY BNTC SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$8.63+4.8% Next Q

Q2 (-2Q)

Grade E$9.04-4% Next Q

Q3 (-1Q)

Grade E$8.68-2.2% Next Q

Current

Grade E$8.49-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BNTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BNTC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.22) and Max Pain ($8.91) forces dealer call-delta covering toward $17.13.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BNTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BNTC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

42.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE7% OF RANGE

L: $8$8.49H: $16

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on BNTC

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and -7.66% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (20)

6/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like BNTC

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BNTC)

✓Walkthrough of BNTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BNTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.30%▼ DESCENDING CHANNEL

2026-11-03O $8.83H $8.83L $8.49C $8.49VOL 135.5K

RES: $13.53SUP: $7.44SMA50: $10.22SMA200: $11.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BNTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BNTC Butterfly Map → + Track BNTC →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +85.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BNTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BNTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BNTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BNTC)

Health Care Rank #795 of 1015 ⚔️ IRD vs BNTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BNTC vs. IRD, VOGX, PRLD, ENTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Benitec Biopharma Inc. (BNTC) ranks #795 by composite RQD confidence (30/100, grade E) and #514 by equity capitalization ($304.9M). Within this direct 5-issuer industry benchmark cohort, BNTC leads on earnings valuation at N/A trailing P/E, while BNTC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with BNTC at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BNTC ACTIVE Benitec Biopharma Inc.	E	30/100	—	—	-35.0%	-2.86%	$304.9M	Benchmark Subject
IRD Opus Genetics Inc.	E	23/100	—	—	-35.0%	+0.82%	$305.3M	/ird-vs-bntc →
VOGX Vogenx Inc	D	45/100	—	—	—	+2.42%	$300.8M	/vogx-vs-bntc →
PRLD Prelude Therapeutics Incorporated	E	33/100	—	—	-35.0%	-1.03%	$309.6M	/prld-vs-bntc →
ENTA Enanta Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	-2.61%	$311.9M	/enta-vs-bntc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001808898 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Benitec Biopharma Inc. (BNTC) reported GAAP revenue of $116.9M (+85.7% vs. FY2024 revenue of $63.0M , and +118.9% cumulative change since FY2023) , GAAP net income of -$37.9M, operating cash flow of -$23.6M, and free cash flow of -$23.6M (-20.5% YoY). On the balance sheet, BNTC closed FY2025 with $190.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$116.9M	-$37.9M	-$23.6M	-$23.6M	$190.7M	—
FY2024 (FY)	2024-06-30	$63.0M	-$21.8M	-$19.4M	-$19.6M	$79.1M	—
FY2023 (FY)	2023-06-30	$53.4M	-$19.6M	-$18.0M	-$18.0M	—	—

3. BNTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BNTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BNTC compare to IRD and VOGX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BNTC?

Where is BNTC trading relative to its 50-day, 200-day, and 52-week technical levels?

BNTC last traded at $8.49 (-2.86% on volume of 240,636 shares), positioning the stock -16.93% below its 50-day simple moving average ($10.22) and -26.24% below its 200-day simple moving average ($11.51). Across its 52-week range of $7.89 to $16.31, BNTC sits at the 7.1% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.43 to $9.55).

Direct Sub-Reports: BNTC RQD Cockpit BNTC 12M Forecast BNTC Earnings & Move BNTC Dividends & DRIP BNTC Insiders & 13F BNTC Whale Options BNTC Profit Sankey BNTC News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

BNTC — Benitec Biopharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Benitec Biopharma Inc. (BNTC) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $8.49 (-2.86% 1D, market capitalization $304.9M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -7.66%.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Benitec Biopharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..3B. Reported revenue in the SEC financials is — across all listed periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Benitec Biopharma Inc. (BNTC) reported $116.9M in annual revenue (up from $63.0M in FY2024, +85.7% YoY) and -$37.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($53.4M revenue, -$19.6M net income) through FY2025, BNTC scaled operating cash flow to -$23.6M and free cash flow to -$23.6M, backed by $190.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.66% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $7.89 – $16.31 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. Investors should watch whether the pivotal-study regulatory path, referenced in the news feed, affects the company's ability to fund operations given its reported negative free cash flow, since the source does not describe the company's funding structure beyond reported cash.

Key Question #1: Can BNTC sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $116.9M and free cash flow of -$23.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is BNTC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BNTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Benitec Biopharma Inc. (BNTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BNTC Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

Yahoo Finance report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Benitec Biopharma Inc. Stock 12‑Month Price Target Raised to $24.33, Implies 171% Upside

TradingView report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

Raymond James initiates Benitec BioPharma stock with outperform rating

Investing.com report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Every patient in Benitec’s study responded to an experimental treatment for a disease that weakens swallowing.

Stock Titan report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Raymond James Initiates Coverage on Benitec Biopharma With Outperform Raring, $14 PT

Yahoo Finance report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Benzinga • 1d ago

This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Benzinga report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine Media • 1d ago

Benitec Biopharma Announces Encouraging Interim Phase 1b/2a Results for BB-301

Kalkine Media report covering Benitec Biopharma Inc. (BNTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 6d ago

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with BB-301 across both d

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BNTC Bull vs. Bear Conversation Board — What's Your Call at $8.49?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BNTC 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $10.75 (+23.0%)

📌 Pinned Debate

Recent news flow includes an FDA regulatory update on the BB-301 pivotal study, an Outperform initiation from Raymond James, and report

The street is overcomplicating Benitec Biopharma Inc. (BNTC). Recent news flow includes an FDA regulatory update on the BB-301 pivotal study, an Outperform initiation from Raymond James, and reported cash rising to $188.8M in FY 2025.. With an RQD score of 30/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $9.44.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 30/100 quality, though with 1.0 beta I'm scaling in with half-size at $8.74 and keeping dry powder in case we test $8.13.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $6.99 (-20.0%)

Spot @ $8.74

The RQD rating of 30 (E) reflects ROIC of -35%, negative free cash flow of -$23.6M in FY 2025, and institutional and insider pillars sc

The RQD rating of 30 (E) reflects ROIC of -35%, negative free cash flow of -$23.6M in FY 2025, and institutional and insider pillars scoring only 3/20 each.. Look at the math on BNTC: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $7.69 before getting long.